Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Biopharm Services Firm Parexel Acquires Taiwanese CRO for US$51 Million (Taiwan)

This article was originally published in PharmAsia News

Executive Summary

U.S.-based contract research organization Parexel International Corp. announced its buyout of Taiwan's Apex International Clinical Research Co. on Sept. 26. Parexel bought the firm, which will now operate as Parexel Apex International, for $50.9 million. Parexel hopes its partnership with Apex will help it to access Asia's growing healthcare and pharmaceutical markets. Apex already supplies the regional medical industry with a number of services including consultations, clinical monitoring, data management, and site management. Asides from its Taiwan headquarters, which has about 350 employees, Apex has several other locations around the region, including China, Hong Kong, Korea, India, Singapore, the Philippines, Malaysian, Indonesia, Thailand, Australia, and New Zealand. Apex's Taiwan location is especially advantageous in light of the fact that as of June 6, 2007, Taiwan had more clinical trials than anywhere else in the area with 532 active trials. Japan came in second with 328, China had 275, and Indian 270. (Click here for more - May Require Free Registration

You may also be interested in...

MNCs Can Access Asian Markets Faster With Bridging Studies – Parexel Exec

With local variations, Asian countries are accepting Phase III data from multinational studies that include patients from their country – even if they live in Los Angeles.

MNCs Can Access Asian Markets Faster With Bridging Studies – Parexel Exec

PERTH, Australia - Global studies that include Asia should be part of any multinational company's strategy to accelerate development time and gain access to the Asian market, a Parexel exec told the recent BioMedical Asia conference in Singapore

Off-Label Use Final Rule: US FDA Declines To Focus Solely On Promotional Claims

In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts